---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-013704"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-01-24T23:59:59+00:00"
generated_at: "2026-06-20T10:53:00.050498+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Verrica resubmits NDA for VP-102 (molluscum contagiosum) to FDA

## Summary
- Resubmitted the New Drug Application for VP-102 to the FDA on January 24, 2023.
- VP-102 is intended for the treatment of molluscum contagiosum.
- No additional details regarding the resubmission content or timeline were disclosed.

## SEC filing metadata
- accession: 0001193125-23-013704
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-01-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523013704/0001193125-23-013704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523013704/d429269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-013704
- JSON: https://secwatch.observer/filing/0001193125-23-013704.json
- Plain text: https://secwatch.observer/filing/0001193125-23-013704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.